Pd l1 pd l2 vista antagonist ca 170

Drug Overview

pd l1 pd l2 vista antagonist ca 170 (CA-170) is a highly innovative, experimental cancer medication. It belongs to a modern class of cancer treatments known as Immunotherapy. Unlike traditional chemotherapy that poisons cancer cells (and healthy cells), this drug is designed to help your body’s own immune system recognize and destroy the cancer. What makes CA-170 unique is that it is taken by mouth as a pill, whereas most other immune-boosting cancer drugs must be given through an IV needle. Currently, it is being tested in clinical trials and is not yet available at standard pharmacies.

• Generic Name: CA-170 (Sometimes referred to as AUPM-170)
• US Brand Names: None (Experimental drug)
• Drug Class: PD-L1, PD-L2, and VISTA Antagonist (Immunotherapy / Targeted Therapy)
• Route of Administration: Oral (Taken by mouth as a capsule or pill)
• FDA Approval Status: Not FDA Approved (Strictly limited to clinical trials and medical research)

What Is It and How Does It Work? (Mechanism of Action)

CA-170 is a cutting-edge Immunotherapy drug. To understand how it works at the molecular level, it helps to think of your immune system as an army of defender cells (called T-cells).

Normally, T-cells patrol your body looking for infections and cancer. However, to stop these T-cells from accidentally attacking your healthy organs, the body has natural “brakes” called immune checkpoints. Cancer cells are very sneaky; they learn to hijack these brakes to hide from the immune system. They coat themselves in specific proteins called PD-L1, PD-L2, and VISTA. When a T-cell bumps into these proteins, its brakes are pulled, and it goes to sleep instead of attacking the cancer.

Here is how CA-170 stops this trick:

• The Triple Blockade: CA-170 is designed to target three specific brake proteins at once: PD-L1, PD-L2, and VISTA.
• Cutting the Connection: The medicine physically attaches to these proteins on the surface of the tumor cells. This puts a “cap” on them, preventing them from connecting with the resting T-cells.
• Releasing the Brakes: Because the tumor can no longer pull the brakes, the T-cells wake up. The immune system recognizes the cancer as a threat and actively attacks and destroys the tumor cells.

FDA-Approved Clinical Indications

Because CA-170 is an investigational research medicine, it has not yet been approved by the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general public use.

Oncological Uses (Investigational Only):

• Advanced solid tumors (such as lung, head and neck, and colon cancers)
• Non-Small Cell Lung Cancer (NSCLC)
• Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Non-oncological Uses:

• None at this time.

Dosage and Administration Protocols

Because CA-170 is still in clinical trials, the exact dosage depends on the specific study a patient joins. The information below reflects the doses used in recent Phase 1 and Phase 2 human clinical trials.

Note: Dosing is highly specific to the clinical trial rules and requires close medical supervision.

Clinical Efficacy and Research Results

Recent clinical research (spanning data from 2020 to 2025) has focused on testing how well CA-170 works in patients whose cancer has stopped responding to standard treatments.

• Safety and Tumor Control: In Phase 1 and Phase 2 trials involving advanced solid tumors, CA-170 proved to be safe and well-tolerated. While it did not make tumors completely disappear for most patients, it achieved “stable disease” in many cases. This means the drug temporarily stopped the cancer from growing or spreading.
• Lymphoma Success: The drug showed its most promising results in patients with Hodgkin Lymphoma. In some early trial groups, roughly 40% to 50% of patients experienced a “clinical benefit,” meaning their tumors either shrank or stopped growing for an extended period.
• Current Focus: Because oral pills are much easier for patients to take than IV drips, researchers are highly interested in CA-170. Current studies are exploring whether combining CA-170 with other traditional cancer drugs or radiation can improve overall survival rates.

Safety Profile and Side Effects

Because CA-170 takes the brakes off the immune system, the immune system can sometimes become overactive and mistakenly attack healthy parts of the body. However, because it is an oral drug, early trials suggest its side effects may be milder than those caused by IV immunotherapy drugs.

Black Box Warning:

There is currently no FDA “Black Box Warning” because the drug is experimental and unapproved.

Common Side Effects (Occurs in >10% of patients)

• Feeling unusually tired or weak (Fatigue)
• Mild upset stomach (Nausea)
• Skin itching (Pruritus)
• Mild skin rashes
• Loss of appetite

Serious Adverse Events

• Immune-Mediated Inflammation: The awakened immune system can attack healthy organs. This can cause severe lung inflammation (pneumonitis), severe bowel inflammation (colitis causing dangerous diarrhea), or liver inflammation (hepatitis).
• Thyroid Problems: The immune system may attack the thyroid gland, causing it to become overactive or underactive.

Management Strategies

• For Immune Reactions: If a patient develops a severe cough, intense diarrhea, or yellowing of the eyes, the doctor will pause the trial drug immediately. The patient is usually given strong steroids (like prednisone) to calm the immune system down.
• For Thyroid Issues: Doctors will check thyroid blood levels frequently. If the thyroid stops working properly, the patient can simply take a daily thyroid replacement hormone pill.
• For Rashes and Itching: Mild steroid creams and oral allergy medicines (antihistamines) are provided to soothe the skin.

Connection to Stem Cell and Regenerative Medicine

The research behind CA-170 is deeply connected to the future of Immunotherapy and regenerative biology. Inside a tumor, the cancer creates a toxic environment that causes attacking T-cells to become “exhausted” and lose their energy. Because CA-170 blocks VISTA (a unique immune checkpoint that heavily suppresses immune cells), scientists are researching how this drug can revive and regenerate these exhausted T-cells. In the laboratory, researchers are exploring how to combine drugs like CA-170 with advanced CAR-T cell therapies (where a patient’s own immune cells are genetically upgraded in a lab and put back into the body). By giving CA-170 alongside these therapies, scientists hope to protect the newly infused cells, allowing them to regenerate properly and fight the cancer without being turned off by the tumor’s defense mechanisms.

Patient Management and Practical Recommendations

Patient safety is the highest priority during a clinical trial. Healthcare teams follow rigorous rules to protect patients receiving investigational immunotherapies.

Pre-treatment Tests to be Performed

• Comprehensive Blood Panel: To check the health of the liver and kidneys before the immune system is activated.
• Thyroid Function Test: A blood test (TSH) to establish a baseline of how well the thyroid is working.
• Lung and Bowel Assessment: A review of the patient’s breathing and digestive habits to watch for future immune-related inflammation.

Precautions During Treatment

• Patients must be highly aware of any new symptoms. An overactive immune system can cause damage quickly, so early reporting of side effects is critical.
• Because the medicine is taken at home, patients must be very responsible about taking the exact dose at the exact right time.

“Do’s and Don’ts” List

• DO swallow the pills exactly as your trial doctor instructs, usually with a full glass of water.
• DO call your doctor immediately if you develop new diarrhea, a dry cough, shortness of breath, or severe stomach pain.
• DO use a good moisturizer daily to prevent dry, itchy skin.
• DON’T take any new over-the-counter medicines, herbal supplements, or vitamins without asking your oncology team first.
• DON’T stop taking the medication just because you feel well; cancer cells can start growing again if the immune brakes are allowed to reset.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. CA-170 is an investigational drug and is not approved by the FDA, EMA, or other global regulatory bodies for commercial use outside of clinical trials. Always consult with your oncologist or a qualified healthcare provider regarding your specific medical condition, clinical trial eligibility, and available, approved treatment options.